ES536654A0 - Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina - Google Patents

Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina

Info

Publication number
ES536654A0
ES536654A0 ES536654A ES536654A ES536654A0 ES 536654 A0 ES536654 A0 ES 536654A0 ES 536654 A ES536654 A ES 536654A ES 536654 A ES536654 A ES 536654A ES 536654 A0 ES536654 A0 ES 536654A0
Authority
ES
Spain
Prior art keywords
nitroxymethyl
chloropyridine
preparing
procedure
occlusion compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES536654A
Other languages
English (en)
Other versions
ES8506758A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of ES8506758A1 publication Critical patent/ES8506758A1/es
Publication of ES536654A0 publication Critical patent/ES536654A0/es
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ES536654A 1983-10-11 1984-10-10 Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina Granted ES536654A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58190345A JPS6081166A (ja) 1983-10-11 1983-10-11 2−ニトロオキシメチル−6−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法

Publications (2)

Publication Number Publication Date
ES8506758A1 ES8506758A1 (es) 1985-08-01
ES536654A0 true ES536654A0 (es) 1985-08-01

Family

ID=16256648

Family Applications (1)

Application Number Title Priority Date Filing Date
ES536654A Granted ES536654A0 (es) 1983-10-11 1984-10-10 Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina

Country Status (18)

Country Link
US (1) US4575548A (es)
EP (1) EP0141300A3 (es)
JP (1) JPS6081166A (es)
KR (1) KR850003414A (es)
CN (1) CN85102133A (es)
AU (1) AU576521B2 (es)
CA (1) CA1248523A (es)
DK (1) DK461184A (es)
ES (1) ES536654A0 (es)
FI (1) FI843944L (es)
GR (1) GR80531B (es)
HU (1) HU194285B (es)
IL (1) IL73076A (es)
NO (1) NO843773L (es)
OA (1) OA07832A (es)
PH (1) PH20203A (es)
PT (1) PT79320B (es)
ZA (1) ZA847350B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
JPS60202115A (ja) * 1984-03-27 1985-10-12 Ichiro Shibauchi エポキシ樹脂用硬化剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
EP1176792A1 (en) * 2000-07-24 2002-01-30 Alcatel Method and apparatus for providing an all digital loop with power-optimised mode
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US11812951B2 (en) 2008-06-17 2023-11-14 Apollo Endosurgery Us, Inc. Endoscopic needle assembly
CA2692211C (en) * 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
CA2831213C (en) 2011-03-27 2016-05-17 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS57142962A (en) * 1981-02-28 1982-09-03 Santen Pharmaceut Co Ltd Cyclodextrin clathrate compound of sulfur-containing compound
JPS6054304B2 (ja) * 1981-10-16 1985-11-29 株式会社バコム ジソピラミド包接化合物
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
DK311683A (da) * 1982-07-26 1984-01-27 Fujisawa Pharmaceutical Co Fremgangsmaade til fremstilling af pyridylalkylnitratforbindelser
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
DE3329517A1 (de) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
DE3337802A1 (de) * 1983-10-18 1985-04-25 Merck Patent Gmbh, 6100 Darmstadt Pharmazeutische zubereitung

Also Published As

Publication number Publication date
ES8506758A1 (es) 1985-08-01
KR850003414A (ko) 1985-06-17
AU576521B2 (en) 1988-09-01
CA1248523A (en) 1989-01-10
US4575548A (en) 1986-03-11
DK461184A (da) 1985-04-12
GR80531B (en) 1985-01-09
JPS6081166A (ja) 1985-05-09
EP0141300A3 (en) 1986-01-29
AU3339984A (en) 1985-04-18
PT79320A (en) 1984-11-01
NO843773L (no) 1985-04-12
FI843944A0 (fi) 1984-10-08
ZA847350B (en) 1985-10-30
CN85102133A (zh) 1987-01-17
PH20203A (en) 1986-10-20
FI843944L (fi) 1985-04-12
IL73076A0 (en) 1984-12-31
HU194285B (en) 1988-01-28
DK461184D0 (da) 1984-09-26
IL73076A (en) 1988-05-31
PT79320B (en) 1986-09-08
OA07832A (fr) 1986-11-20
EP0141300A2 (en) 1985-05-15
HUT36832A (en) 1985-10-28
JPS6245226B2 (es) 1987-09-25

Similar Documents

Publication Publication Date Title
ES536654A0 (es) Un procedimiento para preparar un compuesto de oclusion de 2-nitroximetil-6-cloropiridina
ES554546A0 (es) Un procedimiento para preparar derivados de guanina
ES534751A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES530916A0 (es) Un procedimiento para preparar derivados de pirimidina
ES534694A0 (es) Un procedimiento para preparar cefuroxima sodica
ES537104A0 (es) Un procedimiento para preparar derivados de tiazina
ES541386A0 (es) Un procedimiento para la preparacion de un compuesto
ES527790A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES523195A0 (es) Un procedimiento para preparar alquil-glicosidos
ES537668A0 (es) Un procedimiento para preparar n-formil-3-fenoxi-1-azetidincarboxamidas
MX164160B (es) Un procedimiento para preparar un compuesto neoalcoxi
ES535568A0 (es) Un procedimiento para preparar derivados de piridazinona
ES531550A0 (es) Procedimiento para preparar un fenilaminobencoalcanol
ES537351A0 (es) Un procedimiento para la preparacion de compuestos de -lactama
ES544863A0 (es) Un procedimiento para preparar un compuesto de beta-lactama
ES523193A0 (es) Un procedimiento para preparar 3-fenoxi-1-azetidincarbo-xznmidas
ES536050A0 (es) Un procedimiento para preparar fenil-carbamatos sustituidos
ES534170A0 (es) Un procedimiento para preparar 1-piridil-alquil-4-aril-piperazinas
ES538072A0 (es) Un procedimiento para preparar un difenil-eter
ES535492A0 (es) Un procedimiento para la preparacion de un compuesto de b-lactama
ES529478A0 (es) Un procedimiento para preparar derivados de mitomicina
ES530855A0 (es) Un procedimiento para preparar derivados de benzotiazina
ES530812A0 (es) Un procedimiento para preparar benzoato de triciclohexilestano
AR240938A1 (es) Un procedimiento para preparar un compuesto de imidazoquilina
ES545130A0 (es) Un procedimiento para preparar un compuesto de piridoben- zodiazepina